We are live on ! Find out more
NVCT icon

Nuvectis Pharma
NVCT

31 hedge funds and large institutions have $6.6M invested in Nuvectis Pharma in 2024 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 12 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.94% less ownership

Funds ownership: 6.56% → 5.63% (-0.94%)

13% less capital invested

Capital invested by funds: $7.63M → $6.6M (-$1.03M)

24% less funds holding

Funds holding: 41 → 31 (-10)

25% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 12

77% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 13

Holders
31
Holders Change
-10
Holders Change %
-24.39%
% of All Funds
0.45%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
9
Reduced
12
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
IAM
Iridian Asset Management
Connecticut
+$364K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$329K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$174K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$174K
5
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$95.1K

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$390K
2
Renaissance Technologies
Renaissance Technologies
New York
-$386K
3
Millennium Management
Millennium Management
New York
-$335K
4
Northern Trust
Northern Trust
Illinois
-$227K
5
BlackRock
BlackRock
New York
-$223K
Name Holding Trade Value Shares
Change 		Change in
Stake
HCM
26
Hollencrest Capital Management
California
$1.76K – – –
JP Morgan Chase
27
JP Morgan Chase
New York
$1.21K -$95.8K -14,561 -99%
NS
28
NBC Securities
Alabama
$1K – – –
SPIA
29
Steward Partners Investment Advisory
New York
$629 – – –
Nisa Investment Advisors
30
Nisa Investment Advisors
Missouri
$75 -$1.32K -200 -94%
UBS Group
31
UBS Group
Switzerland
$69 -$13 -2 -15%
Goldman Sachs
32
Goldman Sachs
New York
– -$390K -61,570 Closed
YIH
33
Y-Intercept (HK)
Hong Kong
– -$147K -23,173 Closed
Jane Street
34
Jane Street
New York
– -$108K -17,021 Closed
Citadel Advisors
35
Citadel Advisors
Florida
– -$94.6K -14,937 Closed
HF
36
HRT Financial
New York
– -$86K -13,627 Closed
CC
37
Centiva Capital
New York
– -$84.2K -13,300 Closed
PAS
38
Point72 Asia (Singapore)
Singapore
– -$58.3K -9,203 Closed
Mirae Asset Global ETFs Holdings
39
Mirae Asset Global ETFs Holdings
Hong Kong
– -$20.6K -3,254 Closed
RhumbLine Advisers
40
RhumbLine Advisers
Massachusetts
– -$11.8K -1,871 Closed
PD
41
Point72 (DIFC)
United Arab Emirates
– -$7.91K -1,249 Closed
Macquarie Group
42
Macquarie Group
Australia
– -$2.25K -355 Closed
New York State Common Retirement Fund
43
New York State Common Retirement Fund
New York
– -$405 -64 Closed
1
2

NVCT Hedge Fund Activity: Q3 2024 in Review

31 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Nuvectis Pharma (NVCT) for Q3 2024, worth a combined $6.6M — down 13% from $7.63M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of NVCT and 3 opened new positions — a net loss of 10 holders — while 12 trimmed existing stakes and 9 added.

The largest buyer was Iridian Asset Management, opening a new position worth an estimated $364K. The largest seller was Goldman Sachs, exiting entirely with an estimated $390K sold.

  • 31 institutional investors held Nuvectis Pharma (NVCT) as of Q3 2024, down from 41 in Q2 2024.
  • Funds reported $6.6M of Nuvectis Pharma stock for Q3 2024, down 13% quarter-over-quarter.
  • 3 funds opened new Nuvectis Pharma positions in Q3 2024 and 13 closed out, a net change of -10 holders.
  • The largest Nuvectis Pharma buyer in Q3 2024 was Iridian Asset Management, an estimated $364K added.
  • The largest Nuvectis Pharma seller in Q3 2024 was Goldman Sachs, an estimated $390K sold.

Based on aggregated 13F filings for Q3 2024.